Publications
Articles and Abstracts
Background: With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need. 89Zr-labelled monoclonal antibody ([89Zr]Zr-girentuximab) has high affinity for carbonic anhydrase 9, a tumour antigen highly expressed in clear-cell renal cell carcinoma. We aimed to evaluate [89Zr]Zr-girentuximab PET–CT imaging for detection and characterisation of clear-cell renal cell carcinoma.
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Teresa Alonso Gordoa, MD
The 2024 ESMO Annual Congress was host to the session Updates in the management of advanced renal cell carcinoma. Dr. Teresa Alonso Gordoa discussed systemic treatment options for the management of advanced renal cell carcinoma.
Presented by Peter Mulders, MD, PhD
The 2024 EAU annual congress was host to a plenary session addressing imaging-related controversies for the staging of genitourinary cancers. Professor Peter Mulders discussed why molecular imaging evaluation is the ‘way to go’ for the initial staging of renal cell cancer.
Presented by Marc Bjurlin, DO, MSc, FACOS
The 2024 SESAUA annual meeting featured an AUA Course Lecture and a presentation by Dr. Marc Bjurlin discussing current approaches and future opportunities for integrating molecular imaging into urologic oncology clinical practice. 
Presented by Jeremie Calais, MD, MSc
Jeremie Calais presented the results of the ZIRCON phase 3 trial that evaluated the test performance characteristics of 89Zr-DFO-girentuximab PET/CT imaging for the accurate detection of clear cell RCC primary and secondary lesions in patients with renal masses detected via conventional imaging.
Presented by Jeremie Calais, MD, MSc
The 2023 SNMMI Annual Meeting was host to a session on urologic malignancies. Following his earlier presentation of the ZIRCON phase 3 study results in the overall cohort, Dr. Calais next presented results from the UCLA cohort of this trial.
Presented by Maria Carmen Mir, MD, PhD, FEBU
 The 2023 EAU annual congress was host to a game changing session. Dr. Maria Carmen Mir led the discussant session following Professor Peter Mulders’ earlier presentation of the phase 3 ZIRCON trial results.
Presented by Peter Mulders, MD, PhD
The 2023 EAU annual congress was host to a game changing session. Professor Peter Mulders presented results from the phase 3 ZIRCON study, which evaluated 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma.
Presented by Brian M. Shuch, MD
 The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell RCC.